Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T. Jake Liang; John L.M. Law; Thomas Pietschmann; Stuart C. Ray; Jens Bukh; Rowena Bull; Raymond T. Chung; D. Lorne Tyrrell; Michael Houghton; Charles M. Rice

doi:10.1093/cid/ciad336

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T. Jake Liang^*, John L.M. Law, Thomas Pietschmann, Stuart C. Ray, Jens Bukh, Rowena Bull, Raymond T. Chung, D. Lorne Tyrrell, Michael Houghton, Charles M. Rice

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Journal article › Research › peer-review

3 Citations (Scopus)

Abstract

For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

Original language	English
Journal	Clinical Infectious Diseases
Volume	77
Pages (from-to)	S257-S261
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciad336
Publication status	Published - 2023

Bibliographical note

Publisher Copyright:
© 2023 Oxford University Press. All rights reserved.

Keywords

acute hepatitis
risk-benefit analysis
treatment
vaccine development

Access to Document

10.1093/cid/ciad336

Cite this

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model. / Liang, T. Jake; Law, John L.M.; Pietschmann, Thomas; Ray, Stuart C.; Bukh, Jens; Bull, Rowena; Chung, Raymond T.; Tyrrell, D. Lorne; Houghton, Michael; Rice, Charles M.

In: Clinical Infectious Diseases, Vol. 77, 2023, p. S257-S261.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{1c3013995be74469ac913a3bfa5f311e,

title = "Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model",

abstract = "For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.",

keywords = "acute hepatitis, risk-benefit analysis, treatment, vaccine development",

author = "Liang, {T. Jake} and Law, {John L.M.} and Thomas Pietschmann and Ray, {Stuart C.} and Jens Bukh and Rowena Bull and Chung, {Raymond T.} and Tyrrell, {D. Lorne} and Michael Houghton and Rice, {Charles M.}",

year = "2023",

doi = "10.1093/cid/ciad336",

language = "English",

volume = "77",

pages = "S257--S261",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

AU - Liang, T. Jake

AU - Law, John L.M.

AU - Pietschmann, Thomas

AU - Ray, Stuart C.

AU - Bukh, Jens

AU - Bull, Rowena

AU - Chung, Raymond T.

AU - Tyrrell, D. Lorne

AU - Houghton, Michael

AU - Rice, Charles M.

PY - 2023

Y1 - 2023

N2 - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

AB - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

KW - acute hepatitis

KW - risk-benefit analysis

KW - treatment

KW - vaccine development

U2 - 10.1093/cid/ciad336

DO - 10.1093/cid/ciad336

M3 - Journal article

C2 - 37579208

AN - SCOPUS:85168210876

VL - 77

SP - S257-S261

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -